Advertisement
Screener

EPIZYME, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

EPIZYME, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

EPIZYME, INC. reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$91.25 million for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-09.

Discontinued › Income Statement › Net Income

us-gaap:ProfitLoss · last filed 2022-08-09

  • EPIZYME, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2022-06-30 was -$35.74M.
  • EPIZYME, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2022-03-31 was -$55.51M.
  • EPIZYME, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2021-12-31 was -$50.65M.
  • EPIZYME, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2021-09-30 was -$65.83M.
  • EPIZYME, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2021 was -$251.12M.
  • EPIZYME, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2020 was -$231.69M.
  • EPIZYME, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2019 was -$170.29M.
  • EPIZYME, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2018 was -$123.63M.
Period endNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month
2022-06-30-$35.74M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
-$91.25M
10-Q · filed 2022-08-09
-$141.90M
derived: sum of 3 quarters · filed 2022-08-09
-$207.73M
derived: sum of 4 quarters · filed 2022-08-09
2022-03-31-$55.51M
10-Q · filed 2022-05-10
-$106.16M
derived: sum of 2 quarters · filed 2022-05-10
-$171.99M
derived: sum of 3 quarters · filed 2022-05-10
-$236.35M
derived: sum of 4 quarters · filed 2022-08-09
2021-12-31-$50.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
-$116.48M
derived: sum of 2 quarters · filed 2022-03-01
-$180.85M
derived: sum of 3 quarters · filed 2022-08-09
-$251.12M
10-K · filed 2022-03-01
2021-09-30-$65.83M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09
-$130.20M
derived: sum of 2 quarters · filed 2022-08-09
-$200.47M
10-Q · filed 2021-11-09
-$266.70M
derived: sum of 4 quarters · filed 2022-08-09
2021-06-30-$64.36M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
-$134.64M
10-Q · filed 2022-08-09
-$200.87M
derived: sum of 3 quarters · filed 2022-08-09
-$256.94M
derived: sum of 4 quarters · filed 2022-08-09
2021-03-31-$70.27M
10-Q · filed 2022-05-10
-$136.51M
derived: sum of 2 quarters · filed 2022-05-10
-$192.58M
derived: sum of 3 quarters · filed 2022-05-10
-$251.03M
derived: sum of 4 quarters · filed 2022-05-10
2020-12-31-$66.23M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
-$122.31M
derived: sum of 2 quarters · filed 2022-03-01
-$180.76M
derived: sum of 3 quarters · filed 2022-03-01
-$231.69M
10-K · filed 2022-03-01
2020-09-30-$56.07M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09
-$114.52M
derived: sum of 2 quarters · filed 2021-11-09
-$165.46M
10-Q · filed 2021-11-09
-$221.86M
derived: sum of 4 quarters · filed 2022-03-01
2020-06-30-$58.45M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09
-$109.39M
10-Q · filed 2021-08-09
-$165.79M
derived: sum of 3 quarters · filed 2022-03-01
-$201.88M
derived: sum of 4 quarters · filed 2022-03-01
2020-03-31-$50.94M
10-Q · filed 2021-05-06
-$107.34M
derived: sum of 2 quarters · filed 2022-03-01
-$143.43M
derived: sum of 3 quarters · filed 2022-03-01
-$191.89M
derived: sum of 4 quarters · filed 2022-03-01
2019-12-31-$56.40M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
-$92.49M
derived: sum of 2 quarters · filed 2022-03-01
-$140.96M
derived: sum of 3 quarters · filed 2022-03-01
-$170.29M
10-K · filed 2022-03-01
2019-09-30-$36.09M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06
-$84.55M
derived: sum of 2 quarters · filed 2020-11-06
-$113.89M
10-Q · filed 2020-11-06
-$136.84M
derived: sum of 4 quarters · filed 2021-02-23
2019-06-30-$48.47M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04
-$77.80M
10-Q · filed 2020-08-04
-$100.75M
derived: sum of 3 quarters · filed 2021-02-23
-$138.24M
derived: sum of 4 quarters · filed 2021-02-23
2019-03-31-$29.34M
10-Q · filed 2020-05-04
-$52.28M
derived: sum of 2 quarters · filed 2021-02-23
-$89.78M
derived: sum of 3 quarters · filed 2021-02-23
-$118.90M
derived: sum of 4 quarters · filed 2021-02-23
2018-12-31-$22.95M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23
-$60.44M
derived: sum of 2 quarters · filed 2021-02-23
-$89.56M
derived: sum of 3 quarters · filed 2021-02-23
-$123.63M
10-K · filed 2021-02-23
2018-09-30-$37.49M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31
-$66.62M
derived: sum of 2 quarters · filed 2019-10-31
-$100.69M
10-Q · filed 2019-10-31
-$136.85M
derived: sum of 4 quarters · filed 2020-02-27
2018-06-30-$29.13M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09
-$63.19M
10-Q · filed 2019-08-09
-$99.36M
derived: sum of 3 quarters · filed 2020-02-27
-$136.96M
derived: sum of 4 quarters · filed 2020-02-27
2018-03-31-$34.06M
10-Q · filed 2019-05-06
-$70.23M
derived: sum of 2 quarters · filed 2020-02-27
-$107.83M
derived: sum of 3 quarters · filed 2020-02-27
2017-12-31-$36.17M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27
-$73.76M
derived: sum of 2 quarters · filed 2020-02-27
-$134.31M
10-K · filed 2020-02-27
2017-09-30-$37.60M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-02
-$98.14M
10-Q · filed 2018-11-02
2017-06-30-$60.55M
10-Q · filed 2018-08-02
2016-12-31-$110.21M
10-K · filed 2019-02-26